The oxytocic pharmaceuticals market is expected to grow significantly, nearly doubling in size from USD 133.2 million in 2025 ...

The US government, seeking to fend off a drugmaker’s legal challenge over a federal drug price negotiation program, is ...

FYB203 has been approved by the US FDA and UK Medicines and Healthcare products Regulatory Agency for the treatment ...

Being able to reduce our cost of capital demonstrates great confidence, by a group of experienced healthcare investors, in Alvotech’s leadership, our pipeline progress and prospects for near-term ...

We came across a bullish thesis on Teva Pharmaceutical Industries Limited on Kontra Investments’ Substack by Kontra. In this ...

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacturing of biosimilar medicines ...

The global allergic rhinitis market is poised for substantial growth from 2025 to 2035, driven by a rise in allergic diseases, and advancements in th ...

If you want to support news that works for Greenwood — make a tax-deductible gift today.

Alvotech is also developing AVT29, a proposed biosimilar to Eylea® HD, a higher dose (aflibercept 8 mg) aflibercept. Advanz has licensed the distribution rights from Alvotech for both biosimilar ...

Previous commissioners questions updating the county's juvenile detention center into a residential treatment facility for ...

Detailed price information for Teva Pharmaceutical Industries ADR (TEVA-N) from The Globe and Mail including charting and ...

One of the most directly affected companies is Adani Ports and Special Economic Zone Ltd. (APSEZ). In January 2023, Adani ...